What is William Blair’s Estimate for OVID Q1 Earnings?

Ovid Therapeutics Inc. (NASDAQ:OVID) – Research analysts at William Blair issued their Q1 2026 EPS estimates for shares of Ovid Therapeutics in a research note issued on Wednesday, March 12th. William Blair analyst S. Schram expects that the company will post earnings of ($0.18) per share for the quarter. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. William Blair also issued estimates for Ovid Therapeutics’ Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.18) EPS and Q4 2026 earnings at ($0.19) EPS.

Ovid Therapeutics (NASDAQ:OVID) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. Ovid Therapeutics had a negative net margin of 5,142.56% and a negative return on equity of 39.24%. The business had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.19 million.

Several other brokerages have also recently issued reports on OVID. Wedbush restated an “outperform” rating and set a $3.00 target price (down from $4.00) on shares of Ovid Therapeutics in a research report on Wednesday. Oppenheimer raised shares of Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 target price on the stock in a research report on Wednesday, January 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of Ovid Therapeutics in a research report on Wednesday, December 4th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Ovid Therapeutics has a consensus rating of “Buy” and an average price target of $3.20.

Ovid Therapeutics Stock Down 12.0 %

OVID opened at $0.44 on Thursday. The firm has a 50-day simple moving average of $0.66 and a two-hundred day simple moving average of $0.96. The company has a quick ratio of 5.66, a current ratio of 5.66 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $31.24 million, a PE ratio of -0.94 and a beta of 0.29. Ovid Therapeutics has a 52 week low of $0.44 and a 52 week high of $3.45.

Institutional Investors Weigh In On Ovid Therapeutics

Several institutional investors have recently bought and sold shares of OVID. GSA Capital Partners LLP boosted its stake in Ovid Therapeutics by 118.0% in the third quarter. GSA Capital Partners LLP now owns 260,509 shares of the company’s stock valued at $307,000 after acquiring an additional 141,002 shares in the last quarter. FMR LLC raised its holdings in shares of Ovid Therapeutics by 1,907.4% during the third quarter. FMR LLC now owns 50,225 shares of the company’s stock worth $59,000 after purchasing an additional 47,723 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in Ovid Therapeutics by 4,128.7% in the third quarter. BNP Paribas Financial Markets now owns 220,401 shares of the company’s stock valued at $260,000 after buying an additional 215,189 shares in the last quarter. Verition Fund Management LLC purchased a new position in Ovid Therapeutics in the third quarter valued at $88,000. Finally, XTX Topco Ltd increased its holdings in Ovid Therapeutics by 46.2% in the third quarter. XTX Topco Ltd now owns 38,230 shares of the company’s stock valued at $45,000 after buying an additional 12,076 shares in the last quarter. 72.24% of the stock is currently owned by institutional investors and hedge funds.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.